Bessemer Group’s PDS Biotechnology PDSB Stock Holding History

Bessemer Group’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,146	Closed	-$1K	–	2586
2025 Q1	$1K	Hold	1,146	–	–	﹤0.01%	2369
2024 Q4	$2K	Buy	+1,146	New	+$3.03K	﹤0.01%	2251

Other funds holding PDSB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bessemer Group's PDSB Position: Q2 2025 in Review

Bessemer Group sold out of PDS Biotechnology (PDSB) in Q2 2025, closing a stake of 1,146 shares — an estimated $1K sold.

Bessemer Group first reported a position in PDSB in Q4 2024 and held it in 2 quarters. The position peaked at $2K in Q4 2024. 55 funds tracked by Wall St. Rank hold PDSB as of Q2 2025.

Bessemer Group reported no remaining PDS Biotechnology position as of Q2 2025 after selling out during the quarter.
Bessemer Group sold 1,146 PDS Biotechnology shares in Q2 2025, an estimated $1K.
Bessemer Group first reported a position in PDS Biotechnology in Q4 2024 and held it in 2 quarters.
Bessemer Group's PDS Biotechnology position peaked at $2K in Q4 2024.
55 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2025.

Based on Bessemer Group's 13F filing for Q2 2025, filed 1 Aug 2025.